UBS upgraded Alkermes (NASDAQ:ALKS) to Buy from Neutral on Tuesday, citing prospects for Irish biotech’s orexin 2 receptor ...

Analysts have recently evaluated Alkermes and provided 12-month price targets. The average target is $42.17, accompanied by a ...

First-line maintenance combination therapy reduced the risk of disease progression or death by 46%, with a median overall survival of 13.2 months vs 10.6 months for atezolizumab alone from the ...

"Alkermes is honored to present at these notable scientific meetings, sharing our research and insights with thought leaders and healthcare providers from across the field of psychiatry," said ...

The meetings included: "Alkermes is honored to present at these notable scientific meetings, sharing our research and insights with thought leaders and healthcare providers from across the field ...

Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Alkermes plc (NASDAQ:ALKS) as an investment opportunity by projecting its future cash flows and ...

"Alkermes is at the forefront of development in the orexin 2 receptor agonist therapeutic category; this new investigational mechanism has the potential to transform the treatment paradigm for ...

– New Research Evaluating the Clinical, Economic and Humanistic Burden of Narcolepsy and Findings From In-Depth Qualitative Patient Interviews on the Burden of Idiopathic Hypersomnia Will Also ...

Prior to Inhibikase, Chris held roles of increasing responsibility at Momenta Pharmaceuticals, Lonza, Axial Therapeutics, and Alkermes where he honed his expertise in manufacturing, program and ...